Revenue Breakdown
Composition ()
No data
Revenue Streams
Repligen Corp (RGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue - Filtration products, accounting for 47.7% of total sales, equivalent to $28.88M. Other significant revenue streams include Product revenu - Protein products and Product revenue-Chromatography products. Understanding this composition is critical for investors evaluating how RGEN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Repligen Corp maintains a gross margin of 53.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.14%, while the net margin is 7.90%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RGEN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RGEN competes directly with industry leaders such as PRAX and JAZZ. With a market capitalization of $8.48B, it holds a significant position in the sector. When comparing efficiency, RGEN's gross margin of 53.24% stands against PRAX's N/A and JAZZ's 73.60%. Such benchmarking helps identify whether Repligen Corp is trading at a premium or discount relative to its financial performance.
